Jain Nidhi, Irwin Kathleen, Carlin Linda, Freeman Crystal, Montano Daniel, Kasprzyk Danuta
Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
J Infect Dis. 2007 Jul 1;196(1):76-81. doi: 10.1086/518439. Epub 2007 May 17.
Since 1999, human papillomavirus (HPV) DNA tests have been approved only for abnormal cervical cytology management and as an adjunct to cervical cytology screening. To assess HPV DNA testing practices, we mailed surveys to 6906 randomly selected clinicians in mid-2004. Awareness (87%) and ever use (67%) of HPV DNA tests was high. Test users were more likely than nonusers to be obstetricians/gynecologists or midwives, to be female, and to serve mainly privately insured patients. Respondents reported ever using HPV DNA tests for both approved and nonapproved indications, which included testing for HPV infection in women with anogenital warts or other sexually transmitted diseases, in their sex partners, and in men. Interventions are needed to discourage HPV DNA test use for nonapproved indications.
自1999年以来,人乳头瘤病毒(HPV)DNA检测仅被批准用于异常宫颈细胞学管理以及作为宫颈细胞学筛查的辅助手段。为评估HPV DNA检测的使用情况,我们于2004年年中向6906名随机抽取的临床医生邮寄了调查问卷。HPV DNA检测的知晓率(87%)和曾经使用率(67%)都很高。检测使用者比非使用者更有可能是妇产科医生或助产士,为女性,且主要服务于有私人保险的患者。受访者报告曾将HPV DNA检测用于批准和未批准的指征,包括对患有肛门生殖器疣或其他性传播疾病的女性、其性伴侣以及男性进行HPV感染检测。需要采取干预措施,以抑制将HPV DNA检测用于未批准的指征。